STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2%

PHASE4CompletedINTERVENTIONAL
Enrollment

498

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Dermatitis, Seborrheic
Interventions
DRUG

Ketoconazole

Foam, 2%, Extina will be applied twice daily (morning and evening) to all seborrheic dermatitis lesions on the face, scalp, ears, neck, and chest. Study product should be applied at the first sign of a seborrheic dermatitis flare, and twice daily applications should continue until the area(s) has cleared. All symptom flares should be treated throughout the 12-month study period.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Stiefel, a GSK Company

INDUSTRY